All In Biotech

Drug Trial Radar · NCT07446270

Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies

A Cohort Clinical Study to Evaluate the Efficacy and Safety of Tunlametinib Combined With Anti-EGFR Monoclonal Antibody in Patients With RAS-mutated Advanced Gastrointestinal Malignancies

Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Mar 3, 2026

Primary completion

Oct 30, 2027

Study completion Oct 30, 2028

Sponsor

Lead sponsor
Chinese PLA General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies

Conditions

  • Treatment for Advanced Colorectal Cancer
  • Treatment for Advanced Pancreatic Cancer

Interventions

  • Colorectal cancer: Tunlametinib + cetuximab βDrug

    Colorectal cancer: Tunlametinib 6/9mg bid+ cetuximab β 500mg/m2

  • Pancreatic cancer: Tunlametinib + cetuximab βDrug

    Pancreatic cancer: Tunlametinib 6/9mg+ cetuximab β 500mg/m2

  • Pancreatic cancer: Tunlametinib +NimotuzumabDrug

    Pancreatic cancer: Tunlametinib 6/9mg bid +Nimotuzumab 400mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.